PPAR γ regulates MITF and β-catenin expression and promotes a differentiated phenotype in mouse melanoma S91

Pigment Cell and Melanoma Research

Volumn 21, Issue 3, 2008, Pages 388-396

  Grabacka, Maja ^a   Placha, Wojciech ^c   Urbanska, Krystyna ^b   Laidler, Piotr ^c   Płonka, Przemysław M ^b   Reiss, Krzysztof ^d  

^a UNIVERSITY OF AGRICULTURE IN KRAKOW   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ciglitazone; Differentiation; Microphthalmia associated transcription factor; Spindle morphology; Tyrosinase

Indexed keywords

BETA CATENIN; CIGLITAZONE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; SPINDLE CELL;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SHAPE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; MELANOCYTES; MELANOMA; MICE; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; PHENOTYPE; PPAR GAMMA; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES; TRETINOIN; UP-REGULATION;

EID: 43549113135     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00460.x     Document Type: Article

References (62)

1. Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A., Genua, M., Vigneri, R. Belfiore, A. (2006). Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147, 4463 4475.
2. Altiok, S., Xu, M. Spiegelman, B.M. (1997). PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11, 1987 1998.
3. Anderson, D.J. (1989). The neural crest cell lineage problem: neuropoesis? Neuron 3, 1 12.
4. Bennett, D.C. Medrano, E.E. (2002). Molecular regulation of melanocyte senescence. Pigment Cell Res. 15, 242 250.
5. Bentley, N.J., Eisen, T. Goding, C.R. (1994). Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 14, 7996 8006.
6. Bruserud, O., Gjertsen, B.T., Foss, B. Huang, T.S. (2001). New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells - the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 19, 1 11.
7. Carreira, S., Dexter, T.J., Yavuzer, U., Easty, D.J. Goding, C.R. (1998). Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter. Mol. Cell. Biol. 18, 5099 5108.
8. Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.D., Denat, L., Larue, L. Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764 769.
9. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L. Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426 3439.
10. Chen, F. Harrison, L.E. (2005). Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell. Signal. 17, 809 816.
11. Chen, X., Maniotis, A.J., Majumdar, D., Pe'er, J. Folberg, R. (2002). Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest. Ophthalmol. Vis. Sci. 43, 2533 2539.
12. Coelho, S.M., Vaisman, M. Carvalho, D.P. (2005). Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 11, 2525 2531.
13. Dalhoff, K., Dancey, J., Astrup, L. et al. (2003). A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89, 252 257.
14. Drees, F., Pokutta, S., Yamada, S., Nelson, W.J. Weis, W.I. (2005). Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell 123, 903 915.
15. Du, J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Ross, K., Huber, W.E., Nishimura, E.K., Golub, T.R. Fisher, D.E. (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565 576.
16. Eberle, J., Wagner, M. Macneil, S. (1998). Human melanoma cell lines show little relationship between expression of pigmentation genes and pigmentary behaviour in vitro. Pigment Cell Res. 11, 134 142.
17. Escher, P. Wahli, W. (2000). Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448, 121 138.
18. Folberg, R. Maniotis, A.J. (2004). Vasculogenic mimicry. Apmis 112, 508 525.
19. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117 122.
20. Gershon, T.R., Oppenheimer, O., Chin, S.S. Gerald, W.L. (2005). Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia 7, 575 584.
21. Grabacka, M., Placha, W., Plonka, P.M., Pajak, S., Urbanska, K., Laidler, P. Slominski, A. (2004). Inhibition of melanoma metastases by fenofibrate. Arch. Dermatol. Res. 296, 54 58.
22. Grabacka, M., Plonka, P.M., Urbanska, K. Reiss, K. (2006). Peroxisome proliferator - activated receptor alpha decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 12, 3028 3036.
23. Grichnik, J.M., Burch, J.A., Schulteis, R.D., Shan, S., Liu, J., Darrow, T.L., Vervaert, C.E. Seigler, H.F. (2006). Melanoma, a tumor based on a mutant stem cell? J. Invest. Dermatol. 126, 142 153.
24. Gupta, P.B., Kuperwasser, C., Brunet, J.P., Ramaswamy, S., Kuo, W.L., Gray, J.W., Naber, S.P. Weinberg, R.A. (2005). The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047 1054.
25. Halaban, R. (2002). Pigmentation in melanomas: changes manifesting underlying oncogenic and melabolic activities. Oncol Rev Anti-Cancer Drugs 13, 3 5.
26. Haydon, R.C., Zhou, L., Feng, T. et al. (2002). Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8, 1288 1294.
27. Hemesath, T.J., Steingrimsson, E., Mcgill, G., Hansen, M.J., Vaught, J., Hodgkinson, C.A., Arnheiter, H., Copeland, N.G., Jenkins, N.A. Fisher, D.E. (1994). microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 8, 2770 2780.
28. Hendrix, M.J., Seftor, E.A., Seftor, R.E., Kasemeier-Kulesa, J., Kulesa, P.M. Postovit, L.M. (2007). Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7, 246 255.
29. Hoek, K., Rimm, D.L., Williams, K.R. et al. (2004). Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 5270 5282.
30. Kang, H.Y., Chung, E., Lee, M., Cho, Y. Kang, W.H. (2004). Expression and function of peroxisome proliferator-activated receptors in human melanocytes. Br. J. Dermatol. 150, 462 468.
31. Kersten, S., Mandard, S., Escher, P., Gonzalez, F.J., Tafuri, S., Desvergne, B. Wahli, W. (2001). The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J. 15, 1971 1978.
32. Konopleva, M., Elstner, E., Mcqueen, T.J. et al. (2004). Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3, 1249 1262.
33. Kopelovich, L., Fay, J.R., Glazer, R.I. Crowell, J.A. (2002). Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 1, 357 363.
34. Kuphal, S. Bosserhoff, A.K. (2006). Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene 25, 248 259.
35. Kuphal, S., Palm, H.G., Poser, I. Bosserhoff, A.K. (2005). Snail-regulated genes in malignant melanoma. Melanoma Res. 15, 305 313.
36. Larue, L. Delmas, V. (2006). The WNT/Beta-catenin pathway in melanoma. Front Biosci 11, 733 742.
37. Lens, M.B. Dawes, M. (2004). Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 150, 179 185.
38. Liu, J. Farmer, S.R. (2004). Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J. Biol. Chem. 279, 45020 45027.
39. Liu, J., Wang, H., Zuo, Y. Farmer, S.R. (2006). Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol. Cell. Biol. 26, 5827 5837.
40. Loercher, A.E., Tank, E.M., Delston, R.B. Harbour, J.W. (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 35 40.
41. Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., Trent, J.M., Meltzer, P.S. Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739 752.
42. Mcgill, G.G., Horstmann, M., Widlund, H.R. et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707 718.
43. Murakami, H. Arnheiter, H. (2005). Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res. 18, 265 277.
44. Okuno, M., Kojima, S., Matsushima-Nishiwaki, R., Tsurumi, H., Muto, Y., Friedman, S.L. Moriwaki, H. (2004). Retinoids in cancer chemoprevention. Curr Cancer Drug Targets 4, 285 298.
45. Pantazis, P., Chatterjee, D., Han, Z. Wyche, J. (1999). Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro. Neoplasia 1, 231 240.
46. Patsouris, D., Mandard, S., Voshol, P.J. et al. (2004). PPARalpha governs glycerol metabolism. J. Clin. Invest. 114, 94 103.
47. Pineda Torra, I., Gervois, P. Staels, B. (1999). Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10, 151 159.
48. Placha, W., Gil, D., Dembinska-Kiec, A. Laidler, P. (2003). The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res. 13, 447 456.
49. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E. Polakis, P. (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275, 1790 1792.
50. Saito, H., Yasumoto, K., Takeda, K., Takahashi, K., Yamamoto, H. Shibahara, S. (2003). Microphthalmia-associated transcription factor in the Wnt signaling pathway. Pigment Cell Res. 16, 261 265.
51. Schepsky, A., Bruser, K., Gunnarsson, G.J., Goodall, J., Hallsson, J.H., Goding, C.R., Steingrimsson, E. Hecht, A. (2006). The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol. Cell. Biol. 26, 8914 8927.
52. Slominski, A., Wortsman, J., Carlson, A.J., Matsuoka, L.Y., Balch, C.M. Mihm, M.C. (2001). Malignant melanoma. Arch. Pathol. Lab. Med. 125, 1295 1306.
53. Steingrimsson, E., Copeland, N.G. Jenkins, N.A. (2004). Melanocytes and the Microphthalmia Transcription Factor Network. Annu. Rev. Genet. 38, 365 411.
54. Takeda, K., Yasumoto, K., Takada, R., Takada, S., Watanabe, K., Udono, T., Saito, H., Takahashi, K. Shibahara, S. (2000). Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J. Biol. Chem. 275, 14013 14016.
55. Vignati, S., Albertini, V., Rinaldi, A., Kwee, I., Riva, C., Oldrini, R., Capella, C., Bertoni, F., Carbone, G.M. Catapano, C.V. (2006). Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8, 851 861.
56. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J.C., Staels, B. Auwerx, J. (1995). Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96, 741 750.
57. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Heyman, R.A., Staels, B. Auwerx, J. (1996). Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell. Biol. 16, 3350 3360.
58. Wang, J.Y., Ho, T., Trojanek, J., Chintapalli, J., Grabacka, M., Stoklosa, T., Garcia, F.U., Skorski, T. Reiss, K. (2005). Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence. Oncogene 24, 3748 3758.
59. Welsh, J., Wietzke, J.A., Zinser, G.M., Byrne, B., Smith, K. Narvaez, C.J. (2003). Vitamin D-3 receptor as a target for breast cancer prevention. J. Nutr. 133, 2425S 2433S.
60. Widlund, H.R., Horstmann, M.A., Price, E.R., Cui, J., Lessnick, S.L., Wu, M., He, X. Fisher, D.E. (2002). Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J. Cell Biol. 158, 1079 1087.
61. Winder, A.J. Harris, H. (1991). New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. Eur. J. Biochem. 198, 317 326.
62. Yang, F.G., Zhang, Z.W., Xin, D.Q., Shi, C.J., Wu, J.P., Guo, Y.L. Guan, Y.F. (2005). Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 26, 753 761.